Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

被引：0

作者：

Pro, Barbara ^{[1
]}

Advani, Ranjana H. ^{[2
]}

Brice, Pauline ^{[3
]}

Bartlett, Nancy L. ^{[4
]}

Rosenblatt, Joseph D. ^{[5
]}

Illidge, Tim ^{[6
]}

Matous, Jeffrey V. ^{[7
]}

Ramchandren, Radhakrishnan ^{[8
]}

Fanale, Michelle A. ^{[9
]}

Connors, Joseph M. ^{[10
]}

Yang, Yin ^{[11
]}

Kennedy, Dana A. ^{[11
]}

Shustov, Andrei R. ^{[12
]}

机构：

[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[2] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[3] Hosp St Louis, Paris, France

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[6] Christie Hosp NHS, Manchester, Lancs, England

[7] Colorado Blood Canc Inst, Denver, CO USA

[8] Karmanos Canc Inst, Detroit, MI USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[10] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada

[11] Seattle Genet Inc, Bothell, WA USA

[12] Univ Washington, Med Ctr, Seattle, WA 98195 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.2745.2745

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2745

引用

页数：2

共 50 条

[21] Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Pro, Barbara
Advani, Ranjana H.
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Fenton, Keenan
Huebner, Dirk
Pinelli, Juan
Shustov, Andrei R.
BLOOD, 2016, 128 (22)
[22] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
Fukuhara, Noriko
Yamamoto, Go
Tsujimura, Hideki
Chou, Takaaki
Shibayama, Hirohiko
Yanai, Tomoko
Shibuya, Kazunori
Izutsu, Koji
LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
[23] Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
Liu, Jia
Zheng, Lei
Chuang, Ling-Hsiang
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 99 - 107
[24] Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin
Chihara, Dai
Wong, Shannon
Feldman, Tatyana
Fanale, Michelle A.
Sanchez, Larysa
Connors, Joseph M.
Savage, Kerry J.
Oki, Yasuhiro
HEMATOLOGICAL ONCOLOGY, 2019, 37 (01) : 35 - 38
[25] PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA: INTERIM PHASE 1 SAFETY AND PHARMACOKINETIC DATA
Locatelli, F.
Gore, L.
Mauz-Koerholz, C.
Rosolen, A.
Landman-Parker, J.
de Toledo, J.
Beishuizen, A.
Fasanmade, A.
Wang, J.
Fingert, H.
Labotka, R.
Neville, K.
HAEMATOLOGICA, 2013, 98 : 68 - 68
[26] REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 40 RELAPSED/REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS
Quirini, F.
Broccoli, A.
Pellegrini, C.
Di Rocco, A.
Puccini, B.
Patti, C.
Gini, G.
Mannina, D.
Tani, M.
Rusconi, C.
Romano, A.
Vanazzi, A.
Botto, B.
Carlo-Stella, C.
Hoaus, S.
Musto, P.
Mazza, P.
Molica, S.
Corradini, P.
Fama, A.
Gaudio, F.
Merli, M.
Gravetti, A.
Gritti, G.
Arcari, A.
Tosi, P.
Liberati, A. M.
Pinto, A.
Pavone, V.
Gherlinzoni, F.
Naso, V.
Volpetti, S.
Trentin, L.
Goldaniga, M. C.
Bonfichi, M.
De Renzo, A.
Schiavotto, C.
Spina, M.
Storti, S.
Carella, A. M.
Stefoni, V.
Argnani, L.
Zinzani, P. L.
HAEMATOLOGICA, 2017, 102 : 50 - 51
[27] LONG-TERM FOLLOW-UP RESULTS OF AN ONGOING PIVOTAL STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL)
Smith, S.
Chen, R.
Gopal, A.
Ansell, S.
Rosenblatt, J.
Savage, K.
Connors, J.
Engert, A.
Larsen, E.
Sievers, E.
Younes, A.
HAEMATOLOGICA, 2012, 97 : 456 - 456
[28] BRENTUXIMAB VEDOTIN DESENSITIZATION IN A FEMALE WITH RELAPSED, REFRACTORY, ANAPLASTIC LARGE-CELL LYMPHOMA (ALCL)
Qamar, N.
Cho, S.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A68 - A68
[29] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Senter, Peter D.
Sievers, Eric L.
NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
[30] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D Senter
Eric L Sievers
Nature Biotechnology, 2012, 30 : 631 - 637

← 1 2 3 4 5 →